tiprankstipranks
Trending News
More News >
Medicover (SE:MCOV.B)
:MCOV.B
Advertisement

Medicover AB (MCOV.B) AI Stock Analysis

Compare
1 Followers

Top Page

SE:MCOV.B

Medicover AB

(MCOV.B)

Select Model
Select Model
Select Model
Neutral 59 (OpenAI - 4o)
Rating:59Neutral
Price Target:
kr269.00
▲(5.49% Upside)
Medicover AB's stock score is primarily influenced by its solid financial performance, despite challenges with profitability and high leverage. Technical indicators suggest a bearish trend, and the high P/E ratio indicates potential overvaluation. The lack of earnings call and corporate events data limits further insights.

Medicover AB (MCOV.B) vs. iShares MSCI Sweden ETF (EWD)

Medicover AB Business Overview & Revenue Model

Company DescriptionMedicover AB (publ) provides healthcare and diagnostic services in Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It operates through two segment, Healthcare Services and Diagnostic Services. The company's diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. The company operates 97 clinical laboratories, 733 blood-drawing points, and 26 clinics in 10 countries; and 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. It serves corporate and private customers, and patients, as well as public payers. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.
How the Company Makes MoneyMedicover AB generates revenue through several key streams. Primarily, the company earns income from its healthcare services, which include outpatient and inpatient treatments, consultations, and surgeries performed in its clinics and hospitals. Additionally, Medicover provides health insurance plans that contribute significantly to its revenue, catering to both individual and corporate clients. Laboratory diagnostics also form a substantial part of its revenue model, with a wide array of tests and screenings. The company may also engage in strategic partnerships with businesses and organizations to offer tailored healthcare solutions, enhancing its service offerings and expanding its customer base. Furthermore, Medicover's focus on quality care and patient satisfaction helps drive repeat business and referrals, bolstering its earnings.

Medicover AB Financial Statement Overview

Summary
Medicover AB shows robust revenue growth and improving profitability metrics, with strong cash flow management. However, high leverage poses a potential risk that the company needs to address for long-term stability.
Income Statement
75
Positive
Medicover AB has demonstrated strong revenue growth with a 37.6% increase from 2023 to 2024 and a 21.2% increase from 2022 to 2023. The TTM (Trailing-Twelve-Months) revenue growth rate stands at 3.8%. The gross profit margin for the TTM is 21.9%, showing efficient cost management. EBIT margin has increased slightly to 4.0% in the TTM, while EBITDA margin improved to 13.6%, indicating better operational efficiency. Net profit margin is modest at 1.4% in the TTM, but it reflects steady profitability with potential for future growth.
Balance Sheet
65
Positive
The company's debt-to-equity ratio has increased to 2.55 in the TTM, which indicates high leverage and potential risk if not managed properly. However, the return on equity (ROE) has improved to 6.3% in the TTM, suggesting improved profitability from equity. The equity ratio stands at 22.4% for the TTM, reflecting a stable, though leveraged, capital structure.
Cash Flow
70
Positive
Medicover AB's cash flow is strong, with a free cash flow growth of 6.6% in the TTM. The operating cash flow to net income ratio is high at 8.87, indicating good cash generation relative to profits. The free cash flow to net income ratio of 4.86 further highlights efficient cash flow management, demonstrating the company's ability to convert profits into cash.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.26B2.09B1.75B1.51B1.38B997.80M
Gross Profit508.60M448.30M359.40M335.60M395.00M263.50M
EBITDA340.60M171.20M257.40M215.90M274.90M151.60M
Net Income43.40M16.70M17.60M11.80M101.80M25.80M
Balance Sheet
Total Assets2.32B2.14B1.94B1.83B1.68B1.11B
Cash, Cash Equivalents and Short-Term Investments89.40M82.80M64.40M49.10M277.90M86.80M
Total Debt1.42B1.24B1.00B940.00M764.60M367.40M
Total Liabilities1.83B1.65B1.41B1.32B1.12B627.40M
Stockholders Equity467.40M464.80M496.50M474.70M517.60M448.00M
Cash Flow
Free Cash Flow157.30M139.60M94.50M29.60M114.50M83.50M
Operating Cash Flow281.30M261.90M205.00M170.20M216.70M156.00M
Investing Cash Flow-289.80M-134.70M-119.80M-184.80M-333.60M-126.30M
Financing Cash Flow14.40M-108.00M-73.70M-24.30M164.10M-14.10M

Medicover AB Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price255.00
Price Trends
50DMA
266.73
Negative
100DMA
257.85
Negative
200DMA
231.00
Positive
Market Momentum
MACD
-2.99
Positive
RSI
39.42
Neutral
STOCH
16.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MCOV.B, the sentiment is Neutral. The current price of 255 is below the 20-day moving average (MA) of 261.07, below the 50-day MA of 266.73, and above the 200-day MA of 231.00, indicating a neutral trend. The MACD of -2.99 indicates Positive momentum. The RSI at 39.42 is Neutral, neither overbought nor oversold. The STOCH value of 16.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:MCOV.B.

Medicover AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
€10.18B17.2912.76%1.71%8.38%21.07%
70
Neutral
kr32.19B
70
Neutral
€2.23B10.456.86%2.33%6.74%75.70%
65
Neutral
kr10.32B18.691.75%5.75%48.97%
59
Neutral
kr38.50B79.290.57%15.92%82.51%
57
Neutral
€15.04B58.583.34%15.07%117.65%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:MCOV.B
Medicover AB
255.00
70.71
38.37%
SE:ATT
Attendo AB
68.50
21.86
46.87%
SE:HUM
Humana AB
43.00
9.59
28.70%
SE:AMBEA
Ambea AB
128.30
41.84
48.40%
SE:VIMIAN
Vimian Group AB
28.60
-17.60
-38.10%
SE:ASKER
Asker Healthcare Group AB
84.03
2.03
2.48%

Medicover AB Corporate Events

Medicover Enhances Social Finance Framework for Greater Impact
Aug 27, 2025

Medicover AB has updated its Social Finance Framework to align with the latest International Capital Market Association and Loan Market Association principles. This revision emphasizes Medicover’s commitment to enhancing healthcare accessibility and promoting employee wellbeing, aiming to combine financial strength with social impact. The updated framework, reviewed by DNV, will guide the issuance of social bonds and loans to support eligible projects.

The most recent analyst rating on ($SE:MCOV.B) stock is a Hold with a SEK297.00 price target. To see the full list of analyst forecasts on Medicover AB stock, see the SE:MCOV.B Stock Forecast page.

Medicover Reports Strong Q2 2025 Financial Results with Significant Growth
Jul 24, 2025

Medicover reported strong financial performance in the second quarter of 2025, with a 17.1% increase in revenue to €596.7 million and a 96.5% rise in operating profit to €41.7 million. The company achieved significant margin expansion across all profit measures, driven by robust organic growth and efficiency improvements, particularly in Poland and Romania. The acquisition of CityFit and the integration of Synlab businesses further bolstered results, while the healthcare services and diagnostic services divisions both showed impressive growth.

Medicover AB to Present Q2 2025 Financial Results
Jul 9, 2025

Medicover AB has announced its upcoming Q2 2025 financial results presentation, scheduled for July 24, 2025. The event will feature a conference call led by CEO John Stubbington and CFO Anand Patel, providing insights into the company’s performance and allowing for a Q&A session with media, analysts, and investors.

Medicover Announces Share Structure Adjustment
Jun 30, 2025

Medicover AB has announced a change in its share structure, with 7,675 class A shares converted into class B shares following shareholder requests. As of the last trading day of June 2025, the company has a total of 153,535,195 shares, with the conversion affecting the distribution of votes among the different classes of shares. This adjustment in share structure may impact the company’s governance and voting dynamics.

Medicover Appoints New Chief Digital Information Officer
Jun 18, 2025

Medicover AB has announced the appointment of Lukasz Krause as the new Chief Digital Information Officer (CDIO), effective 1 July 2025. Krause, who has been with Medicover for three years as the Head of IT for the Healthcare Services division, brings extensive IT management experience from international corporations. He succeeds Jarek Urbanczyk, who is leaving after nearly six years. The company believes Krause’s expertise will ensure technology continues to drive Medicover’s future success.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 25, 2025